Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 12/20 | 0.44 |
| ▸ | DRD2 | P14416 | 10/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 6/20 | 0.41 |
| ▸ | SRC | P12931 | 5/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10206663 | 0.94 | DRD3 (0.49) | DRD3DRD2CYP4F2CYP4A11KDR | |
| Trifluoroacetic Acid SCHEMBL710679 | 0.92 | ACHE (0.44) | DRD3DRD2 | |
| Trifluoroacetic Acid SCHEMBL712076 | 0.90 | RUNX1 (0.43) | DRD3DRD2GRM4 | |
| SCHEMBL10206662 | 0.83 | ACHE (0.51) | DRD3DRD2 | |
| Trifluoroacetic Acid SCHEMBL720615 | 0.82 | GCK (0.45) | — | |
| SCHEMBL10206661 | 0.81 | ACHE (0.49) | KDRSRC | |
| Trifluoroacetic Acid SCHEMBL713667 | 0.81 | GCK (0.47) | — | |
| Trifluoroacetic Acid SCHEMBL713011 | 0.81 | GCK (0.44) | — | |
| Trifluoroacetic Acid SCHEMBL709188 | 0.79 | GCK (0.39) | — | |
| Trifluoroacetic Acid SCHEMBL709569 | 0.79 | DHODH (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940837-B1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| EP-1940837-A2 | IMIDAZOPYRIDINE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | DRD3 3549/4885DRD2 3228/4885CYP4F2 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.